Zobrazeno 1 - 10
of 104
pro vyhledávání: ''
Autor:
Waleed S. Al Amri, William E. Hughes, James L. Thorne, Geoff Wells, Ian M. Carr, Brian V Hogan, Thomas A. Hughes, Fiona Langlands, Arindam Pramanik, Layla K. Younis, Stacey J. Jones, Sarah A. Harris, Eldo T. Verghese, Rebecca Millican-Slater, Nevine M.F. El Deeb, Mervat A. Hamza, Baek Kim, Noha Gwili
Publikováno v:
British Journal of Cancer
Background Breast cancer stem cells (BCSCs) are drivers of therapy-resistance, therefore are responsible for poor survival. Molecular signatures of BCSCs from primary cancers remain undefined. Here, we identify the consistent transcriptome of primary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99a64defdd7881cec05092b3963a5ac9
https://eprints.whiterose.ac.uk/174958/7/s41416-021-01484-w.pdf
https://eprints.whiterose.ac.uk/174958/7/s41416-021-01484-w.pdf
Autor:
Ring, A., Battisti, N.M.L., Reed, M.W.R., Herbert, E., Morgan, J.L., Bradburn, M., Walters, S.J., Collins, K.A., Ward, S.E., Holmes, G.R., Burton, Maria, Lifford, K., Edwards, A., Robinson, T.G., Martin, C., Chater, T., Pemberton, K.J., Brennan, A., Cheung, K.L., Todd, A., Audisio, R.A., Wright, J., Simcock, R., Green, T., Revell, D., Gath, J., Horgan, K., Holcombe, C., Winter, M.C., Naik, J., Parmeshwar, R., Gosney, M.A., Hatton, M.Q., Thompson, A.M., Wyld, L., Collins, K., Ward, S., Holmes, G., Morgan, J., Walters, S., Burton, M., Brain, K., Robinson, T., Pemberton, K., Shrestha, A., Nettleship, A., Richards, P., Harder, H., Audisio, R., Murray, C., Thomson, A.M., Gosney, M., Hatton, M., Armitage, F., Patnick, J., Revill, D., Winter, M.
Publikováno v:
British Journal of Cancer
Background Chemotherapy improves outcomes for high risk early breast cancer (EBC) patients but is infrequently offered to older individuals. This study determined if there are fit older patients with high-risk disease who may benefit from chemotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ed056944ecd27827ab3bd963813fe40
http://sro.sussex.ac.uk/id/eprint/101218/1/s41416-021-01388-9.pdf
http://sro.sussex.ac.uk/id/eprint/101218/1/s41416-021-01388-9.pdf
Autor:
James L. Thorne, Melina C. Teske, Robyn V. Broad, Andrew M. Hanby, Laura M. Wastall, Stacey J. Jones, Thomas A. Hughes
Publikováno v:
British Journal of Cancer
Background Triple negative breast cancers (TNBC) have poor prognoses despite aggressive treatment with cytotoxic chemotherapy. Cancer-associated fibroblasts (CAFs) are prominent in tumour stroma. Our hypothesis was that CAFs modulate chemotherapy sen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::027115557c95f3f47f1ecb119dec9f3d
Autor:
Sylwia Kopijasz, Corran Roberts, Victoria Y Strauss, Shibani Nicum, Andrew R Clamp, Marcia Hall, Richard D. Kennedy, Ana Montes, Charlie Gourley, Jacinta Abraham, Michael R.L. Stratford, Susana Banerjee, Lisa K. Folkes
Publikováno v:
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4, https://doi.org/10.1038/s41416-019-0674-4
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4
British Journal of Cancer
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4
British Journal of Cancer
BackgroundTumour cells with BRCA1/2 gene mutations demonstrate increased sensitivity to platinum and poly (ADP-ribose) polymerase (PARP) inhibitors. 6-mercaptopurine (6MP) was found to selectively kill BRCA-defective cells in a xenograft model as eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2b494bdec4a88dbce8776a6e9b65b9c
https://doi.org/10.1038/s41416-019-0674-4
https://doi.org/10.1038/s41416-019-0674-4
Autor:
Lusine Tumyan, Daniel Schmolze, Joanne E. Mortimer, Daniel Abler, David A. Hormuth, Angela M. Jarrett, Vikram Adhikarla, Prativa Sahoo, Thomas E. Yankeelov, Russell C. Rockne
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
Jarrett, Angela M.; Hormuth, David A.; Adhikarla, Vikram; Sahoo, Prativa; Abler, Daniel; Tumyan, Lusine; Schmolze, Daniel; Mortimer, Joanne; Rockne, Russell C.; Yankeelov, Thomas E. (2020). Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer. Scientific reports, 10(1), p. 20518. Springer Nature 10.1038/s41598-020-77397-0
Scientific Reports, Vol 10, Iss 1, Pp 1-14 (2020)
Jarrett, Angela M.; Hormuth, David A.; Adhikarla, Vikram; Sahoo, Prativa; Abler, Daniel; Tumyan, Lusine; Schmolze, Daniel; Mortimer, Joanne; Rockne, Russell C.; Yankeelov, Thomas E. (2020). Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer. Scientific reports, 10(1), p. 20518. Springer Nature 10.1038/s41598-020-77397-0
While targeted therapies exist for human epidermal growth factor receptor 2 positive (HER2 +) breast cancer, HER2 + patients do not always respond to therapy. We present the results of utilizing a biophysical mathematical model to predict tumor respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34d692269c2e8a618712ec30483dae71
Autor:
Chris Twelves, Matthew Guo, Larisa Reyderman, Ishtiaq Husain Zubairi, R. Morrison, Nicola Cresti, Claudio Savulsky, Alan Anthoney, Vladimir Semiglazov, Ruth Plummer, T.R. Jeffry Evans, Constanta Timcheva
Publikováno v:
British Journal of Cancer
Background: \ud Capecitabine and eribulin are widely used as single agents in metastatic breast cancer (MBC) and have nonoverlapping toxicities.\ud \ud Methods: \ud In phase 1b (dose escalation), patients with advanced, treatment-refractory, solid tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97bccd2276eddef510b3a7b2fcc67aa0
https://eprints.whiterose.ac.uk/148290/1/s41416-018-0366-5.pdf
https://eprints.whiterose.ac.uk/148290/1/s41416-018-0366-5.pdf
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
[Background] Current therapeutic strategies that are used to combat breast cancer vary widely and largely depend on its clinicopathological features, including tumor subtype, size, stage, lymph node involvement, the presence of hormone receptors and/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff6f37dcbb5ea82449e8289a41c8b7ba
http://hdl.handle.net/10261/201673
http://hdl.handle.net/10261/201673
Autor:
Zsuzsanna Varga, Thomas Ruhstaller, Ulrike Perriard, Dirk Klingbiel, Tilman T. Rau, Jean-Christophe Tille, Beat Thuerlimann, Hanne Hawle, Qiyu Li, Wolfram Jochum
Publikováno v:
Varga, Zsuzsanna; Li, Qiyu; Jochum, Wolfram; Perriard, Ulrike; Rau, Tilman; Tille, Jean-Christoph; Hawle, Hanne; Klingbiel, Dirk; Thuerlimann, Beat; Ruhstaller, Thomas (2019). Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort. Scientific reports, 9(1), p. 13534. Springer Nature 10.1038/s41598-019-49638-4
Scientific Reports, Vol 9, Iss 1, Pp 1-11 (2019)
Scientific Reports, Vol. 9, No 1 (2019) P. 13534
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-11 (2019)
Scientific Reports, Vol. 9, No 1 (2019) P. 13534
Scientific Reports
The assessment of Ki-67 in early-stage breast cancer has become an important diagnostic tool in planning adjuvant therapy, particularly for the administration of additional chemotherapy to hormone-responsive patients. An accurate determination of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::509ed0eb6c511bb431eb561f8c240921
Autor:
I.A.M. Mandjes, Esther H. Lips, Bas B. Koolen, Lennart Mulder, Sjoerd Rodenhuis, Jelle Wesseling, L. Wessels, J. J. de Ronde
Publikováno v:
Breast Cancer Research and Treatment
Breast cancer research and treatment, 140(1), 63-71. Springer New York
Breast cancer research and treatment, 140(1), 63-71. Springer New York
Intrinsic subtypes are widely accepted for the classification of breast cancer. Lacking gene expression data, surrogate classifications based on immunohistochemistry (IHC) have been proposed. A recent St. Gallen consensus meeting recommends to use th
Autor:
Tianfeng Wang, Ai-ping Lu, Yiqiang Liu, Yijun Zhou, Zhaoqing Fan, Tao Ouyang, Yuntao Xie, Jinfeng Li, Yingjian He
Publikováno v:
Breast Cancer Research and Treatment
This study aimed to compare the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer. Five-hundred and one patients with clinical stage I-III invasive breast cancer were randomly assig